“We are now entering a crucial period in Polarean's development and I look forward to providing our shareholders with further updates as appropriate," said chief executive Richard Hullihen.
() has raised £2.1mln through a share placing to strengthen the company’s balance sheet and to support phase III clinical trials and product launch planning.
The medical-imaging technology firm issued more than 11.6mln ordinary shares at a price of 18p each.
"We thank our shareholders for their support on this placing which will enable the swift completion of enrolment for the clinical trials via the addition of a third trial site at the University of Cincinnati, allow us to focus our undivided attention on completion of the new drug application and submission following readout and provide valuable resource for post submission launch preparation and planning," said chief executive Richard Hullihen.
"We are now entering a crucial period in Polarean's development and I look forward to providing our shareholders with further updates as appropriate."
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE